Diabetes Tsunami? China Eyes More Modern Therapies Under 2025 Plan
Executive Summary
Diabetes poses a triple whammy and is likely to cripple China's health care system in near future. To counter, the Chinese government looks at total disease management, long-acting insulins and GLP-1 products.
You may also be interested in...
AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.